Supernus Pharmaceuticals (SUPN) Other Non-Current Assets (2011 - 2026)
Supernus Pharmaceuticals (SUPN) posted quarterly Other Non-Current Assets of $55.0 million for Q2 2026, down 2.55% on a QoQ basis from $56.5 million in Q1 2026.
Supernus Pharmaceuticals (SUPN) Other Non-Current Assets (2011 - 2026) Analysis & Trends
Supernus Pharmaceuticals has reported Other Non-Current Assets for 16 years, with the latest figure at $55.0 million in Q2 2026.
- Other Non-Current Assets for Q2 2026 came in at $55.0 million, changed N/A year-over-year; the trailing twelve-month figure through Jun 2026 was $55.0 million (changed N/A YoY), and the FY2025 annual result was $63.8 million, up 102.35% from the prior year.
- Other Non-Current Assets declined to $55.0 million in Q2 2026, from $56.5 million in the prior quarter.
- Over five years, Other Non-Current Assets peaked at $403.8 million in Q1 2023 and troughed at $31.5 million in Q4 2024.
- A 5-year average of $71.6 million and a median of $44.3 million in 2022 frame the typical range for Other Non-Current Assets.
- The widest annual swing landed in 2023, when Other Non-Current Assets jumped 724.32%; it then sank 90.5% in 2024.
- A 5-year view of Other Non-Current Assets shows it stood at $39.8 million in 2022, then decreased by 2.47% to $38.8 million in 2023, then dropped by 18.79% to $31.5 million in 2024, then soared by 102.35% to $63.8 million in 2025, then dropped by 13.76% to $55.0 million in 2026.
- Per Business Quant data, the three most recent Other Non-Current Assets figures were $55.0 million in Q2 2026, $56.5 million in Q1 2026, and $63.8 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - | 56.35 Mn |
| 2 | Teva Pharmaceutical Industries | 42.98 Bn | 39.32 Bn | 2.15 Bn | 1.79 Bn |
| 3 | Zoetis | 31.53 Bn | 29.86 Bn | 1.05 Bn | 384.00 Mn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 503.80 Mn |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn | 239.50 Mn |
| 6 | Viatris | 18.74 Bn | 17.85 Bn | 1.46 Bn | 1.06 Bn |
| 7 | Neurocrine Biosciences | 15.51 Bn | 15.12 Bn | 935.80 Mn | 59.30 Mn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | 304.00 Mn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.95 Bn | - | 13.00 Mn |
| 10 | Supernus Pharmaceuticals | 2.75 Bn | 2.37 Bn | 185.39 Mn | 55.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 55.02 Mn |
| Mar 31, 2026 | 56.45 Mn |
| Dec 31, 2025 | 1.45 Mn |
| Sep 30, 2025 | 1.45 Mn |
| Jun 30, 2025 | 27.96 Mn |
| Dec 31, 2024 | 31.53 Mn |
| Jun 30, 2024 | 35.89 Mn |
| Mar 31, 2024 | 38.37 Mn |
| Sep 30, 2023 | 38.82 Mn |
| Jun 30, 2023 | 38.49 Mn |
| Mar 31, 2023 | 403.76 Mn |
| Dec 31, 2022 | 39.81 Mn |
| Sep 30, 2022 | 41.29 Mn |
| Jun 30, 2022 | 47.34 Mn |
| Mar 31, 2022 | 48.99 Mn |
| Dec 31, 2021 | 49.23 Mn |
| Sep 30, 2021 | 40.13 Mn |
| Jun 30, 2021 | 40.69 Mn |
| Mar 31, 2021 | 30.26 Mn |
| Dec 31, 2020 | 43.25 Mn |